Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

471

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

October 27, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule

Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

BIOLOGICAL

Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule

Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

BIOLOGICAL

High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule

Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

BIOLOGICAL

Placebo on a 0- and 28-day schedule

Two doses of placebo at the vaccination schedule of day 0,28

Trial Locations (1)

610041

West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu

All Listed Sponsors
collaborator

West China Second University Hospital

OTHER

collaborator

Yunnan Center for Disease Control and Prevention

OTHER

lead

Institute of Medical Biology, Chinese Academy of Medical Sciences

OTHER

NCT04470609 - Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years | Biotech Hunter | Biotech Hunter